Global Short Bowel Syndrome Drugs Market Size By Type (Oral Route, Parental Route), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Short Bowel Syndrome (SBS) Drugs Market was valued at USD 948 million in 2023 and is projected to reach USD 1.78 billion by 2031, growing at a CAGR of 8.2% during the forecast period from 2023 to 2031. The market’s growth is driven by increasing prevalence of gastrointestinal disorders, rising awareness of rare disease treatments, and advancements in recombinant human growth hormone and GLP-2 analogs for SBS management. Short bowel syndrome, a malabsorptive condition caused by the surgical removal or malfunction of large portions of the small intestine, often requires specialized pharmacological management, creating significant demand for targeted therapies.

Drivers:

1. Rising Prevalence of Gastrointestinal Disorders:

Growing incidence of gastrointestinal surgeries due to Crohn’s disease, trauma, or congenital abnormalities has led to an increased number of SBS cases globally.

2. Growing Awareness and Diagnosis of Rare Diseases:

Improved diagnostic capabilities and increased awareness campaigns are leading to earlier and more accurate diagnosis of SBS, boosting demand for effective drug therapies.

3. Advancements in SBS Drug Development:

The development of GLP-2 analogs like teduglutide has transformed SBS treatment by reducing dependence on parenteral nutrition, enhancing patient outcomes and quality of life.

Restraints:

1. High Cost of Therapy:

The annual treatment cost of SBS drugs, particularly teduglutide, can be prohibitively expensive, limiting access in cost-sensitive and low-income regions.

2. Limited Patient Population:

Despite being a life-altering condition, SBS remains a rare disorder. The limited patient base challenges economies of scale and can constrain commercial interest and pricing flexibility.

Opportunity:

1. Expansion into Emerging Markets:

Increasing healthcare expenditure, expanding diagnostic infrastructure, and rare disease policies in emerging markets like Brazil, India, and China are expected to open up growth avenues.

2. Pipeline Progress in Drug Development:

Multiple clinical trials are underway exploring novel GLP-2 receptor agonists and adjunctive therapies to teduglutide, which may offer improved efficacy or affordability.

Market by Drug Class Insights:

The GLP-2 analogs segment dominated the market in 2023, driven by the success of teduglutide (Gattex/Revestive), which reduces the need for parenteral support. Growth hormone-based therapies, though historically used, are gradually losing share due to adverse effects and limited efficacy. Others, including antidiarrheal and adjunctive agents, represent supportive care but not primary drivers of therapy.

Market by End-Use Insights:

Hospitals were the leading end-users in 2023, accounting for over 45% of the market share, due to the complex initiation and monitoring requirements for SBS drug therapy. Home care settings are gaining traction as improved drug formulations and home-infusion support services allow SBS patients to transition away from hospital-based care.

Market by Regional Insights:

North America held the largest share of the SBS drugs market in 2023, fueled by high healthcare spending, access to rare disease medications, and favorable reimbursement structures. Europe followed closely, supported by strong regulatory frameworks for orphan drugs. The Asia-Pacific region is projected to witness the fastest growth, propelled by improving access to advanced therapies and increasing diagnostic rates.

Competitive Scenario:

Key players in the global SBS drugs market include Takeda Pharmaceutical Company Limited, Merck KGaA, Novo Nordisk A/S, Ironwood Pharmaceuticals, Hanmi Pharmaceuticals, and Napo Pharmaceuticals. These companies focus on clinical trials, strategic collaborations, and regulatory approvals to strengthen their market presence.

Recent Developments:

2023: Takeda reported significant patient adoption of Gattex in both North America and the EU.

2024: Ironwood Pharmaceuticals initiated Phase II trials for a novel oral therapy targeting nutrient absorption in SBS patients.

2025: Hanmi Pharmaceuticals expanded its distribution network in Asia for GLP-2 analog candidates under development.

Scope of Work – Global Short Bowel Syndrome Drugs Market

Key Market Developments:

Takeda's Gattex achieved expanded reimbursement in several EU markets in 2023.

Merck KGaA explored biosimilar collaborations for cost-effective GLP-2 therapies.

Hanmi Pharmaceuticals announced early positive results from Phase I studies on a next-gen SBS drug candidate in 2024.

FAQs:

1) What is the current market size of the Global Short Bowel Syndrome Drugs Market?

The market was valued at USD 948 million in 2023.

2) What is the major growth driver of the Global Short Bowel Syndrome Drugs Market?

The increasing prevalence of gastrointestinal surgeries and advancements in SBS-specific drug therapies.

3) Which is the largest region during the forecast period in the Global Short Bowel Syndrome Drugs Market?

North America remains the largest region due to favorable reimbursement and higher diagnosis rates.

4) Which segment accounted for the largest market share in Global Short Bowel Syndrome Drugs Market?

The GLP-2 analogs segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Short Bowel Syndrome Drugs Market?

Key players include Takeda Pharmaceutical, Merck KGaA, Novo Nordisk, Ironwood Pharmaceuticals, and Hanmi Pharmaceuticals.